TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24961325

Group type: EXPERIMENTAL
Intervention: Neovasculogen (plasmid genetic construction containing human gene VEGF165) at a course dose of 2.4 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional vascular therapy
Number of subjects: 100
Study: 22429362

Group type: EXPERIMENTAL
Intervention: Terlipressin infusion at 1.0‐4.0 μg/kg per h
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Terlipressin infusion
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Terlipressin infusion >2.0 μg/kg per h during the preanhepatic phase
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control treatment (generally accepted inotropic and vasopressor agents)
Number of subjects: 41
Study: 20407429

Group type: EXPERIMENTAL
Intervention: Intraductal ultrasonography (IDUS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Other imaging methods without IDUS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Invasive IPMN with preoperative IDUS
Number of subjects: 40

Group type: COMPARATOR
Intervention: Other imaging methods for invasive IPMN
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Noninvasive IPMN
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall survival rate
Number of subjects: 40
Study: 18757528

Group type: EXPERIMENTAL
Intervention: Psychiatric consultation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Psychotropic medication
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Emotional communication with physicians
Number of subjects: 100
Study: 16311183

Group type: EXPERIMENTAL
Intervention: Sublingual (SL) liquid buprenorphine
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Sublingual (SL) tablet buprenorphine
Number of subjects: 57
Study: 12425406

Group type: EXPERIMENTAL
Intervention: Fluid augmentation during the first 36 hours after surgery
Number of subjects: 166

Group type: COMPARATOR
Intervention: Standard postoperative replacement fluids
Number of subjects: 166
Study: 10353976

Group type: EXPERIMENTAL
Intervention: Parent-applied EMLA
Number of subjects: 41

Group type: COMPARATOR
Intervention: Clinician-applied EMLA
Number of subjects: 41
Study: 8678366

Group type: EXPERIMENTAL
Intervention: Pathologically organ-confined cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-specimen-confined prostate cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cancer that has spread through the capsule
Number of subjects: 0
Study: 1892146

Group type: EXPERIMENTAL
Intervention: Ofloxacin, 400 mg every 12 hours, administered orally or by nasogastric tube
Number of subjects: 147

Group type: COMPARATOR
Intervention: Usual care (individual investigator's best selection of therapy administered parenterally)
Number of subjects: 147
Study: 6660930

Group type: EXPERIMENTAL
Intervention: 0.5 mg intracervical prostaglandin E2 (PGE2) gel
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin infusion
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 0.5 mg intracervical prostaglandin E2 (PGE2) gel followed by i.v. oxytocin
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 0.5 mg intracervical prostaglandin E2 (PGE2) gel followed by another dose of PGE2-gel and subsequent i.v. oxytocin
Number of subjects: 54
Study: 30850409

Group type: EXPERIMENTAL
Intervention: Universal PrEP offer following standardised counselling (10 clinics)
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Risk screening with partner self‐test option (Targeted arm, 10 clinics)
Number of subjects: 4000
Study: 29905617

Group type: EXPERIMENTAL
Intervention: Guideline publication period
Number of subjects: 326993

Group type: COMPARATOR
Intervention: Preguideline period
Number of subjects: 326993

Group type: EXPERIMENTAL
Intervention: Postguideline period
Number of subjects: 326993
Study: 27993166

Group type: EXPERIMENTAL
Intervention: mHealth intervention (twice-weekly voice messages about diabetes prevention and control)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Participatory community group intervention (monthly group meetings for men and women to address diabetes issues)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control arm (no intervention)
Number of subjects: 96
Study: 25262125

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents
Number of subjects: 443

Group type: COMPARATOR
Intervention: Sirolimus-eluting stents
Number of subjects: 443
Study: 22188557

Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel (2.5 g)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel (5.0 g)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 1.62% testosterone gel (2.5 g) with t-shirt
Number of subjects: 24

Group type: COMPARATOR
Intervention: 1.62% testosterone gel (any dose) with washing
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel (upper arms/shoulders application site)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel (any dose)
Number of subjects: 24
Study: 20406865

Group type: EXPERIMENTAL
Intervention: Home ultraviolet B phototherapy
Number of subjects: 196

Group type: COMPARATOR
Intervention: Outpatient ultraviolet B phototherapy
Number of subjects: 196
Study: 17696483

Group type: EXPERIMENTAL
Intervention: Organically grown apples
Number of subjects: 6

Group type: COMPARATOR
Intervention: Conventionally grown apples
Number of subjects: 6
Study: 15705646

Group type: EXPERIMENTAL
Intervention: Fasted exercise (F)
Number of subjects: 9

Group type: COMPARATOR
Intervention: CHO exercise (CHO)
Number of subjects: 9
Study: 11976158

Group type: EXPERIMENTAL
Intervention: Whole-grain diet
Number of subjects: 11

Group type: COMPARATOR
Intervention: Refined-grain diet
Number of subjects: 11
Study: 9799202

Group type: EXPERIMENTAL
Intervention: L-arginine infusion
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Hypercholesterolemic (HC) subjects
Number of subjects: 49
Study: 7614530

Group type: EXPERIMENTAL
Intervention: NIF CC 30 mg daily
Number of subjects: 228

Group type: COMPARATOR
Intervention: NIF GITS 30 mg daily
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: NIF GITS 60 mg daily
Number of subjects: 228

Group type: COMPARATOR
Intervention: NIF CC 60 mg daily
Number of subjects: 228
Study: 2575719

Group type: EXPERIMENTAL
Intervention: remoxipride
Number of subjects: 29

Group type: COMPARATOR
Intervention: haloperidol
Number of subjects: 29
Study: 341942

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 47

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 31856791

Group type: EXPERIMENTAL
Intervention: Web-based physical activity platform (ActivOnline) for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 29065653

Group type: EXPERIMENTAL
Intervention: Mechanical goniometer (MGR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Motion analysis system (MAS)
Number of subjects: 30
Study: 25838290

Group type: COMPARATOR
Intervention: PCV10
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 0
Study: 23686821

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) 40mg administered subcutaneously three times weekly (tiw) for 12 months
Number of subjects: 1404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1404
Study: 21518294

Group type: COMPARATOR
Intervention: Spontaneous healing
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Gelfoam patching
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Edge-approximation plus gelfoam patching
Number of subjects: 91
Study: 19592823

Group type: EXPERIMENTAL
Intervention: Technology-enhanced practice (TEP) model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care delivered by home care nurses
Number of subjects: 0
Study: 16818541

Group type: EXPERIMENTAL
Intervention: Early-intervention program consisting of 8 sessions before discharge and 4 home visits by specially trained nurses.
Number of subjects: 214

Group type: COMPARATOR
Intervention: Preterm control group (no intervention).
Number of subjects: 214

Group type: COMPARATOR
Intervention: Term control group (no intervention).
Number of subjects: 214
Study: 14971626

Group type: EXPERIMENTAL
Intervention: Siberian ginseng
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 10757252

Group type: EXPERIMENTAL
Intervention: Amitriptyline (100 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9323616

Group type: COMPARATOR
Intervention: RV3 rotavirus vaccine (1 mL oral dose, 6.5 x 10(5) FFU/mL)
Number of subjects: 30
Study: 7870966

Group type: EXPERIMENTAL
Intervention: Alprazolam (APZ) 0.003 mg/kg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Alprazolam (APZ) 0.007 mg/kg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Alprazolam (APZ) 0.02 mg/kg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Alprazolam (APZ)
Number of subjects: 7
Study: 3759744

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31427872

Group type: EXPERIMENTAL
Intervention: HIIT‐R (running HIIT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: HIIT‐F (functional HIIT)
Number of subjects: 15
Study: 29949873

Group type: EXPERIMENTAL
Intervention: Synbiotics (2.5 g once daily for 12 weeks)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 27926473

Group type: EXPERIMENTAL
Intervention: 75g oral glucose load (OGTT)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Short-term fasting
Number of subjects: 22

Group type: COMPARATOR
Intervention: Carbohydrate-rich meal
Number of subjects: 22

Group type: COMPARATOR
Intervention: Fat-rich meal
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: OGTT in severely obese patients pre- and post-bariatric surgery
Number of subjects: 22
Study: 24766747

Group type: EXPERIMENTAL
Intervention: 1,25(OH)2 D levels
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 25-OH levels
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Liver and respiratory co-morbidity
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Renal co-morbidity
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 300
Study: 22545251

Group type: EXPERIMENTAL
Intervention: Zirconia crowns and fixed partial dentures (FPDs) using Cercon, ZirkonZahn, Lava, and Katana systems
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Katana zirconia system
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Cercon zirconia system
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Lava zirconia system
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Implant-supported crowns
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: FPDs
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Katana FPDs
Number of subjects: 59
Study: 20235836

Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg twice daily
Number of subjects: 484

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Acyclovir (with estimated adherence 90%)
Number of subjects: 484
Study: 18234565

Group type: EXPERIMENTAL
Intervention: Exogenous catecholamines (adrenergic group)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Non-adrenergic treatment (control group)
Number of subjects: 44
Study: 15695976

Group type: EXPERIMENTAL
Intervention: Estradiol 17beta
Number of subjects: 664

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 664
Study: 12866327

Group type: EXPERIMENTAL
Intervention: Experimental case‐based educational modules + personal prescribing feedback
Number of subjects: 207

Group type: COMPARATOR
Intervention: Experimental case‐based educational modules
Number of subjects: 207
Study: 10368449

Group type: EXPERIMENTAL
Intervention: Anthracycline treatment (cumulative doses between 45 and 1150 mg/m2, median 270 mg/m2)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control data matched for body surface area
Number of subjects: 125
Study: 8654629

Group type: EXPERIMENTAL
Intervention: Uniplant (nomegestrol acetate)
Number of subjects: 15
Study: 2050093

Group type: EXPERIMENTAL
Intervention: Wholemeal bread (50 g available carbohydrate)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: White bread (50 g available carbohydrate)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Grained wholemeal rye bread (50 g available carbohydrate)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Grained wholemeal rye bread with 40% dried figs (50 g available carbohydrate)
Number of subjects: 7
Study: 6407502

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (150 mg daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Chlorimipramine (150 mg daily)
Number of subjects: 32
Study: 31365298

Group type: EXPERIMENTAL
Intervention: Spiration Valve System (SVS) with medical management
Number of subjects: 172

Group type: COMPARATOR
Intervention: Medical management alone
Number of subjects: 172
Study: 28954586

Group type: EXPERIMENTAL
Intervention: Night duty (sleep deprivation and fatigue)
Number of subjects: 6
Study: 25205320

Group type: EXPERIMENTAL
Intervention: Probiotic consortium (Lab4) plus 50 mg vitamin C
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 23752299

Group type: EXPERIMENTAL
Intervention: 20 min interruption period
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: 30 min interruption period
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: 60 min interruption period
Number of subjects: 311
Study: 22332067

Group type: EXPERIMENTAL
Intervention: 120‐kVp MNR group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 80‐kVp MNR group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 80‐kVp HNR group
Number of subjects: 60

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 60
Study: 19483114

Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 1218

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 1218
Study: 16706246

Group type: EXPERIMENTAL
Intervention: Metronidazole 1% gel
Number of subjects: 0
Study: 15274037

Group type: EXPERIMENTAL
Intervention: SSRIs (fluvoxamine or paroxetine) for 6 weeks
Number of subjects: 221
Study: 11759644

Group type: EXPERIMENTAL
Intervention: Intravenous fluconazole for six weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 9043599

Group type: EXPERIMENTAL
Intervention: Osteotomy with abrasion arthroplasty (Group A)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Osteotomy alone (Group B)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 88
Study: 7930766

Group type: EXPERIMENTAL
Intervention: Preoperative radiochemotherapy followed by radical surgery
Number of subjects: 268

Group type: COMPARATOR
Intervention: Radical surgery alone
Number of subjects: 268
Study: 3422682

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (two chemotherapeutic regimens)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Surgical management aspects (interval from first symptoms to definitive surgery, surgical sequence, type of surgery)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Above knee amputation
Number of subjects: 166

Group type: COMPARATOR
Intervention: Tibial allograft
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Chemotherapy after recurrence
Number of subjects: 166
Study: 30875961

Group type: EXPERIMENTAL
Intervention: Lotus Seed (LS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Adzuki Bean (AB)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Waxy Black Rice (BR)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Other Starchy Foods
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lotus Seed (LS) and Adzuki Bean (AB)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pre-soaking
Number of subjects: 10
Study: 28368941

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (100 μg)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Continuous ropivacaine wound infusion (0.2%)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control (NaCl 0.9%)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 192
Study: 24443965

Group type: EXPERIMENTAL
Intervention: Mindful Transition to Parenthood Program
Number of subjects: 13
Study: 23418863

Group type: EXPERIMENTAL
Intervention: Lifestyle Wellness Program (LWP) - 12-week group intervention, one-hour weekly sessions discussing dietary choices, lifestyle, physical activity, and self-esteem.
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard Care (SC) - control group without the lifestyle intervention.
Number of subjects: 160
Study: 21198573

Group type: EXPERIMENTAL
Intervention: 5 mg frovatriptan
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 18294832

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 13

Group type: COMPARATOR
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 13
Study: 16565362

Group type: EXPERIMENTAL
Intervention: High-dose retinol (50,000 IU oral retinol for 30 days)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 14687749

Group type: EXPERIMENTAL
Intervention: Alcohol sclerotherapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Silver nitrate insertion
Number of subjects: 22
Study: 12220802

Group type: EXPERIMENTAL
Intervention: Psychiatric group intervention
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study: 9805726

Group type: EXPERIMENTAL
Intervention: Antenatal care services offered according to Cochrane Pregnancy and Childbirth Database (PCD) criteria
Number of subjects: 2913

Group type: EXPERIMENTAL
Intervention: Vaginal examination, evaluation of pelvic size, dental examination, external version for breech presentation, formal risk score classification
Number of subjects: 2913

Group type: EXPERIMENTAL
Intervention: Screening and laboratory tests
Number of subjects: 2913

Group type: EXPERIMENTAL
Intervention: Traditional 'Western' schedule for ANC
Number of subjects: 2913
Study: 7651456

Group type: EXPERIMENTAL
Intervention: Tolcapone (50-800 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tolcapone
Number of subjects: 10
Study: 2629642

Group type: EXPERIMENTAL
Intervention: Education programme consisting of two packages of education with four weekly meetings
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Education programme
Number of subjects: 119
Study: 5766124

Group type: EXPERIMENTAL
Intervention: Synthetic oestrogen, stilboestrol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pure progestogen, megestrol acetate
Number of subjects: 0
Study: 28143731

Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conventional open surgery
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 62
Study: 25655226

Group type: EXPERIMENTAL
Intervention: XR-NTX (injections)
Number of subjects: 7687

Group type: COMPARATOR
Intervention: Non-XR-NTX (control group)
Number of subjects: 7687
Study: 23036842

Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation and aerobic exercise
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Classic stretching physiotherapy intervention
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 74
Study: 22219100

Group type: EXPERIMENTAL
Intervention: Total cholesterol treatment goal (< 4.5 mmol/L)
Number of subjects: 1714

Group type: EXPERIMENTAL
Intervention: Triglycerides treatment goal (< 1.7 mmol/L)
Number of subjects: 1714

Group type: EXPERIMENTAL
Intervention: LDL cholesterol treatment goal (< 2.6 mmol/L)
Number of subjects: 1714

Group type: EXPERIMENTAL
Intervention: HDL cholesterol treatment goal (> 1.0 mmol/L in men and > 1.3 mmol/L in women)
Number of subjects: 1714

Group type: EXPERIMENTAL
Intervention: Blood pressure (BP) goal below 130/80 mm Hg
Number of subjects: 1714

Group type: EXPERIMENTAL
Intervention: Blood pressure (BP) goal below 140/90 mm Hg
Number of subjects: 1714

Group type: EXPERIMENTAL
Intervention: Meeting three treatment goals (HbA1c, BP and cholesterol)
Number of subjects: 1714

Group type: EXPERIMENTAL
Intervention: Meeting two out of three treatment goals
Number of subjects: 1714

Group type: EXPERIMENTAL
Intervention: Meeting only one out of three treatment goals
Number of subjects: 1714
Study: 19805643

Group type: EXPERIMENTAL
Intervention: Aspirin at bedtime
Number of subjects: 16

Group type: COMPARATOR
Intervention: Aspirin at awakening
Number of subjects: 16
Study: 16943683

Group type: EXPERIMENTAL
Intervention: Cockcroft-Gault (CG)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: simplified MDRD (sMDRD)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: mean Cr-Ur
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Cockcroft-Gault (CG) in higher CP (> 0.90; n = 44)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: simplified MDRD (sMDRD) in higher CP (> 0.90; n = 44)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Cockcroft-Gault (CG) in patients aged < or =64 (n = 44)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: simplified MDRD (sMDRD) in patients aged < or =64 (n = 44)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Cockcroft-Gault (CG) in lower CP (< or =0.90; n = 43)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: simplified MDRD (sMDRD) in lower CP (< or =0.90; n = 43)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: mean Cr-Ur in lower CP (< or =0.90; n = 43)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: mean Cr-Ur in older age (>64 years; n = 43)
Number of subjects: 87
Study: 15542159

Group type: EXPERIMENTAL
Intervention: dl-alpha tocopheryl acetate 500 mg twice a day orally plus pentoxifylline 400 mg twice a day orally
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 11379741

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated tapered pins
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard tapered pins
Number of subjects: 20
Study: 8985079

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FS)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (no fibrin sealant)
Number of subjects: 21